Fierce Pharma
AUGUST 9, 2023
AstraZeneca is often at the forefront when it comes to sustainability efforts among pharma companies. Now, the British drugmaker is doubling down on its clean energy commitments in Sweden.
PM360
AUGUST 9, 2023
Real Chemistry , a leading provider of AI-driven insights and marketing and communications for the healthcare industry, is partnering with WhizAI , a generative AI-powered analytics platform purpose-built for life sciences and healthcare, to develop a patient journey visualization and analytics solution. This new platform promises to make it easier for clients to access accurate, contextual insights by asking conversational questions while also having the ability to visualize the process patient
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 9, 2023
After a whistleblower lawsuit accused Takeda and its subsidiaries of Medicaid fraud through illegal reimbursement arrangements and paid referrals in Texas, the company has agreed to pay more than $ | A whistleblower lawsuit accused the drugmaker of paying nurse educators to recommend ADHD drug Vyvanse to providers. Now, Takeda is paying tens of millions of dollars to resolve the case.
Pharmaceutical Technology
AUGUST 9, 2023
The global pharmaceutical industry experienced a 52% decline in the number of artificial intelligence related patent applications in Q2 2023 compared with the previous quarter, according to GlobalData's Patent Analytics.
Fierce Pharma
AUGUST 9, 2023
Another off-the-shelf, BCMA-directed drug has arrived for the treatment of multiple myeloma. | Another off-the-shelf, BCMA-directed drug has arrived for the treatment of multiple myeloma. Pfizer's new Elrexfio will challenge Johnson & Johnson's entrenched position in the market.
MedCity News
AUGUST 9, 2023
Physicians often diagnose patients with chronic kidney disease (CKD) too late in the process, when dialysis is the only option left. This isn’t negligence on the part of physicians — it’s simply a consequence of a fee-for-service (FFS) healthcare model that works against patients’ financial well-being and deemphasizes preventative care.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
AUGUST 9, 2023
The global pharmaceutical industry experienced a 52% decline in the number of artificial intelligence related patent applications in Q2 2023 compared with the previous quarter, according to GlobalData's Patent Analytics.
Fierce Pharma
AUGUST 9, 2023
After striking out in the pandemic phase of COVID-19 with its belated vaccine, Novavax seeks to recover in the endemic phase. | After striking out in the pandemic phase of COVID-19 with its belated vaccine, Novavax seeks to recover in the endemic phase. And a big part of the company's plan centers around enhancing its partnership with SK Bioscience.
PharmaVoice
AUGUST 9, 2023
Children’s Tumor Foundation president Annette Bakker is working to teach the industry the crucial difference between drug repurposing and drug repositioning.
European Pharmaceutical Review
AUGUST 9, 2023
According to research from GlobalData, the pharmaceutical industry is shifting towards development of antibody-drug conjugates (ADC) as oncology treatments. The data showed that Daiichi Sankyo , Seagen and Roche are currently three of the most important companies in the ADC market. Daiichi Sankyo was predicted to remain the dominant player in this market.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
AUGUST 9, 2023
M&A activity in the healthcare sector continued to decline in the second quarter of 2023, with the number of deals reaching its lowest point in three years. However, a new report predicted that M&A activity could increase in the second half of this year due to healthcare companies’ continually shrinking valuations and their divestitures of non-core assets.
Medgadget
AUGUST 9, 2023
Researchers at the University of Würzburg in Germany have developed a portable scanner that is the first to be able to image humans using Magnetic Particle Imaging (MPI). The technology could provide a radiation-free alternative to techniques such as X-ray fluoroscopy and digital subtraction angiography for minimally invasive endovascular procedures, and is well suited for viewing processes such as blood flow.
MedCity News
AUGUST 9, 2023
Senator Mark Warner (D-Virginia) penned a letter to Google leadership expressing concerns about Med-PaLM 2 — the company’s generative AI tool for healthcare providers that is currently being used by Mayo Clinic and other health systems. The letter requested that Google provide more clarity about its chatbot’s training, accuracy, ethical considerations and deployment in healthcare settings.
Nixon Gwilt Law
AUGUST 9, 2023
One of the greatest challenges facing the U.S. healthcare system is access to equitable care for our most vulnerable patient populations. In many cases, practitioners are forced to work around barriers to care posed by social determinants of health (SDOH). In the proposed 2024 Medicare Physician Fee Schedule (MPFS), the Centers for Medicare and Medicaid Services (CMS) proposes new CPT codes to facilitate reimbursement for healthcare providers who help patients overcome social and environmental h
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
AUGUST 9, 2023
Flagship Pioneering-founded Alltrna is developing tRNA therapies to address genetic diseases driven by truncated versions of proteins. By addressing an aberrant genetic instruction underpinning many diseases, the startup is developing what it describes as a potential “universal solution.
Medgadget
AUGUST 9, 2023
Researchers at the University of Ottawa have developed a light-activated hydrogel treatment for corneal disease. Many of the people who suffer from corneal disease, which can include corneal thinning, are not suitable for a corneal transplant, and obtaining transplants is a challenge for those who are. This technology is intended to assist with thickening and reshaping the cornea, and it may pave the way for an alternative to transplants in the future.
PharmExec
AUGUST 9, 2023
The pharmaceutical industry must have crisis communications prepared now to anticipate unforeseen events—especially those that impact public trust.
MedCity News
AUGUST 9, 2023
Traditionally offering family building support, Progyny is expanding into the menopause space. Employees of its employer customers will receive a personalized care plan that includes support for nutrition, sleep, mental health and hormonal health — all factors that affect menopause.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Commerce
AUGUST 9, 2023
Stephanie Smith Cooney joins PBM business to further develop partnerships, especially with independent pharmacists in local communities.
Pharmaceutical Technology
AUGUST 9, 2023
Eli Lilly and Company has posted reported net income of $1.76bn in the second quarter (Q2) of 2023 as against $952.5m in Q2 2022.
MedCity News
AUGUST 9, 2023
Peter Long of Blue Shield of California discusses how they focus on member experience and ways to improve their overall healthcare needs.
Pharmaceutical Technology
AUGUST 9, 2023
The agreement for selling Scilex Holding Company stocks would raise funds to pay off Sorrento’s outstanding debts.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Integrity Solutions
AUGUST 9, 2023
And Improve Deal Velocity & Win Rates Along the Way… Sales cycles are already longer than we want. That’s a reality most of us have been operating in for a number of years now. But what happens when the opportunities stretch out even further ? Lately it seems as though more variables keep adding to the delay. Customers’ buying processes have slowed.
Pharmaceutical Technology
AUGUST 9, 2023
AGC has extended its Milan manufacturing facility to address the growing clinical trial and commercial demands.
European Pharmaceutical Review
AUGUST 9, 2023
Positive top-line results from Novartis’ Phase III REMIX-1 and REMIX-2 studies showed that remibrutinib 25mg b.i.d. facilitated rapid symptom control for chronic spontaneous urticaria (CSU), also known as chronic hives, within two weeks of treatment. The Bruton’s tyrosine kinase (BTK) inhibitor was evaluated in patients with symptoms inadequately controlled by H1-antihistamines.
Pharmaceutical Technology
AUGUST 9, 2023
Ageing populations, rising obesity levels, and low staff retention have created a global healthcare crisis.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
MedCity News
AUGUST 9, 2023
ACA Marketplace insurers are proposing an average 6% premium hike for 2024, with inflation being a driving factor, according to an analysis by KFF.
PharmaTimes
AUGUST 9, 2023
Treatment will help reduce the risk of heart attacks and strokes for patients across Scotland - News - PharmaTimes
PharmExec
AUGUST 9, 2023
Strategy includes a layoff of nearly 400 employees.
Pharma Marketing Network
AUGUST 9, 2023
The pharmaceutical industry operates in a highly regulated environment, where marketing and advertising practices are subject to rigorous scrutiny. Navigating these regulatory challenges is essential to ensure compliance, maintain trust, and effectively communicate the benefits and risks of pharmaceutical products. In this blog post, we will explore best practices for pharmaceutical companies to navigate the complex landscape of regulatory challenges in marketing. 1.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
246 
Let's personalize your content